Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Abstract:Fluorodeoxyglucose positron emission tomography (PET) studies have found that patients with Alzheimer's dementia (AD) have abnormally low rates of cerebral glucose metabolism in posterior cingulate, parietal, temporal, and prefrontal cortex. We previously found that cognitively normal, late-middle-aged carriers of the apolipoprotein E ε4 allele, a common susceptibility gene for late-onset Alzheimer's dementia, have abnormally low rates of glucose metabolism in the same brain regions as patients with probable AD. We now consider whether ε4 carriers have these regional brain abnormalities as relatively young adults. Apolipoprotein E genotypes were established in normal volunteers 20–39 years of age. Clinical ratings, neuropsychological tests, magnetic resonance imaging, and PET were performed in 12 ε4 heterozygotes, all with the ε3/ε4 genotype, and 15 noncarriers of the ε4 allele, 12 of whom were individually matched for sex, age, and educational level. An automated algorithm was used to generate an aggregate surface-projection map that compared regional PET measurements in the two groups. The young adult ε4 carriers and noncarriers did not differ significantly in their sex, age, educational level, clinical ratings, or neuropsychological test scores. Like previously studied patients with probable AD and late-middle-aged ε4 carriers, the young ε4 carriers had abnormally low rates of glucose metabolism bilaterally in the posterior cingulate, parietal, temporal, and prefrontal cortex. Carriers of a common Alzheimer's susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia.
暂无分享,去 创建一个
[1] A. Brun,et al. Distribution of cerebral degeneration in Alzheimer's disease , 1976, Archiv für Psychiatrie und Nervenkrankheiten.
[2] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[3] G. Alexander,et al. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.
[4] Chester A. Mathis,et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.
[5] G. Alexander,et al. Apolipoprotein E and Intellectual Achievement , 2002, Journal of the American Geriatrics Society.
[6] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[7] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[8] Richard J. Caselli,et al. Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease , 2001, Clinical Neuroscience Research.
[9] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] I. Deary,et al. Childhood mental ability and dementia , 2000, Neurology.
[11] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] V. Hachinski,et al. Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. , 2000, Archives of neurology.
[13] J. Baron,et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. , 1999, Brain : a journal of neurology.
[14] K. Ishii,et al. Lack of Association of Apolipoprotein E ε4 Allele Dose with Cerebral Glucose Metabolism in Alzheimer Disease , 1998 .
[15] J. Kessler,et al. Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease , 1998, Neuroscience Letters.
[16] H. Braak,et al. High Frequency of Apolipoprotein E ϵ4 Allele in Young Individuals with Very Mild Alzheimer's Disease-Related Neurofibrillary Changes , 1998, Experimental Neurology.
[17] C. Cotman,et al. Learning upregulates brain-derived neurotrophic factor messenger ribonucleic acid: a mechanism to facilitate encoding and circuit maintenance? , 1998, Behavioral neuroscience.
[18] Daniel Bandy,et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease , 1998, Annals of neurology.
[19] D. Feng,et al. Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography, 18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] G. Alexander,et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.
[21] Karl J. Friston,et al. Human Brain Function , 1997 .
[22] H. Arai,et al. Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1‐antichymotrypsin type A allele in Alzheimer's disease , 1997, Neuroreport.
[23] H. Braak,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[24] E. Corder,et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. , 1997, Archives of neurology.
[25] R J Mark,et al. Amyloid β-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation , 1997, The Journal of Neuroscience.
[26] M. First,et al. Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .
[27] P Pietrini,et al. Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. , 1997, The American journal of psychiatry.
[28] Jonathan D. Smith,et al. Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.
[29] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[30] D R Wekstein,et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. , 1996, JAMA.
[31] D E Kuhl,et al. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] P. Magistretti,et al. Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. , 1996, Cerebral cortex.
[33] N. Risch,et al. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.
[34] A. Alavi,et al. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] N. Foster,et al. Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.
[36] R. Koeppe,et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] D. Schaid,et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.
[38] J C Mazziotta,et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.
[39] Richard S. J. Frackowiak,et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.
[40] H. Braak,et al. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes , 1995, Neuroscience.
[41] T Vogel,et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. , 1994, The American journal of pathology.
[42] R. Mahley,et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.
[43] R. Mayeux,et al. Influence of education and occupation on the incidence of Alzheimer's disease. , 1994, JAMA.
[44] K Herholz,et al. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. , 1994, Dementia.
[45] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[46] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[47] J V Haxby,et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. , 1993, Dementia.
[48] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[49] M. Albert,et al. Level of education and change in cognitive function in a community population of older persons. , 1993, Annals of epidemiology.
[50] M J de Leon,et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.
[51] C. Coffey,et al. Quantitative cerebral anatomy of the aging human brain , 1992, Neurology.
[52] E. Boerwinkle,et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. , 1991, American journal of human genetics.
[53] C. Degueldre,et al. Decrease of frontal metabolism demonstrated by positron emission tomography in a population of healthy elderly volunteers. , 1991, Acta neurologica Belgica.
[54] M. Torrens. Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .
[55] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[56] B. L. Beattie,et al. 18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial Scans , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[57] Robert L. Spitzer,et al. User's guide for the Structured clinical interview for DSM-III-R : SCID , 1990 .
[58] M. Albert,et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.
[59] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[60] G. V. Van Hoesen,et al. Perforant pathway changes and the memory impairment of Alzheimer's disease , 1986, Annals of neurology.
[61] Michael E. Phelps,et al. Effects of Human Aging on Patterns of Local Cerebral Glucose Utilization Determined by the [18F] Fluorodeoxyglucose Method , 1982, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[62] W J Schwartz,et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. , 1979, Science.
[63] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[64] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.